dmt.clinic

DMT clinical research (research, not treatment access)

Educational only. dmt.clinic is operated by AdvancedCare USA Inc. It is not a clinic, provides no medical advice, makes no referrals to providers, and sells no substances. N,N-DMT and 5-MeO-DMT are Schedule I under U.S. federal law (21 U.S.C. §812; 21 C.F.R. §1308.11; as of 2026-07-21). The only general lawful U.S. pathway discussed here is FDA/DEA-authorized research. Trial listings are research participation information, not a “find a clinic” service and not a way to “get DMT.”

Why this page exists

People search for DMT research for many reasons: academic interest, curiosity about news headlines, or personal hope for future therapies. This page maps what human research has measured and how to read public trial registries. It does not evaluate whether any individual should enroll in a study, and it does not claim that research findings equal approved treatment.

For federal legal framing, see legal status. For risk information without instructions, see harm reduction.

A short history of modern human DMT research

Strassman IV-DMT studies (1990s)

Rick Strassman’s work at the University of New Mexico in the 1990s reopened carefully controlled intravenous N,N-DMT research in humans after a long gap. Those studies measured dose–response physiology and subjective effects under medical monitoring. They are foundational human pharmacology references — not an outpatient treatment model and not a public protocol.

Imperial College continuous-infusion and neuroimaging work

Later work associated with Imperial College London (including Timmermann and colleagues) used controlled administration and brain measures such as EEG and fMRI to study neural correlates of the DMT state. Notable public papers include:

  • Timmermann et al., Scientific Reports (2019) — neural correlates of the DMT experience
  • Subsequent continuous-infusion / imaging work including 2023 publications (e.g. PNAS continuous IV DMT work discussed in the research community)

Reported themes in this literature include changes in oscillatory activity (e.g. reduced alpha-band power), increased signal diversity, and frameworks that interpret the state under predictive-processing ideas. Those are scientific hypotheses and measurements, not consumer benefits.

5-MeO-DMT company and academic programs

5-MeO-DMT has attracted separate development interest (including programs associated with GH Research and other sponsors). Public disclosures have described Phase 2 depression-related research activity. As of early 2026 / mid-2026 editorial checks, placebo-controlled evidence remains more limited than marketing headlines sometimes imply. Always read the actual study design, endpoints, sample size, and whether results are peer-reviewed or press-released.

No efficacy claim is stated here as settled medical fact. Depression scores in open-label or early-phase settings can improve for many reasons (expectation, concurrent care, natural history). Regulators decide approval; this site does not.

What “clinical trial” means here

TermMeaning on this site
Clinical trialA research study with protocol, ethics oversight, and eligibility rules
INDFDA Investigational New Drug pathway for studying a drug in humans
Schedule I researchAdditional DEA researcher controls for Schedule I substances
TreatmentAn approved clinical product or standard-of-care pathway — not what DMT is federally today for the public

Enrollment is not “going to a psychedelic clinic for DMT.” It is research participation under a sponsor’s protocol. Sponsors set inclusion/exclusion criteria (diagnosis, age, meds, prior treatments, location). We do not screen you, refer you, or contact sites on your behalf.

How to read a ClinicalTrials.gov listing

ClinicalTrials.gov is the U.S. public registry for many interventional studies. A practical reading order:

  1. NCT ID — unique study identifier (cite this, not a screenshot).
  2. Status — Recruiting / Active not recruiting / Completed / Terminated / Unknown. Status drifts; re-check.
  3. Conditions & interventions — confirm the molecule and the indication being studied.
  4. Eligibility — inclusion/exclusion; many people who want to enroll will not qualify.
  5. Locations & contacts — official study contacts only; ignore third-party “we can get you in” middlemen.
  6. Sponsor / collaborators — who is responsible for the science and regulatory filings.
  7. Results — many studies post results late or not at all; absence of results ≠ success.

What to ignore

  • Social media posts that rephrase a trial as “DMT therapy now available”
  • Paid lead-gen sites that blur research and commercial treatment
  • Any claim that a trial is a backdoor to recreational supply

Our homepage Active DMT clinical trials tool is a curated educational linker into ClinicalTrials.gov. It finds studies, not providers.

Snapshot discipline (as-of dating)

Trial landscapes change weekly. When you quote counts (“N recruiting studies”), stamp the date you queried ClinicalTrials.gov. This page’s framing was last editorially checked 2026-07-21. For a live search, use:

Reading results without overclaiming

When a press release says “rapid reduction in depression scores,” check:

  1. Open-label vs blinded — expectation effects are large in psychedelic research.
  2. Sample size and follow-up length — short-term change is not durable efficacy.
  3. Comparator — improvement vs baseline is weaker evidence than improvement vs placebo or active control.
  4. Population — trial participants are screened; results do not automatically generalize.
  5. Regulatory status — peer-reviewed signals ≠ FDA approval.

As of 2026-07-21, neither N,N-DMT nor 5-MeO-DMT is an FDA-approved outpatient psychiatric product for general clinical use. Research findings can be scientifically interesting and still not be “available treatment.”

How this connects to other pages

Sources (checked 2026-07-21)

  • Strassman RJ et al. — 1990s IV N,N-DMT human studies (dose-response / subjective effects under medical monitoring).
  • Timmermann C et al. (2019). Neural correlates of the DMT experience. Scientific Reports.
  • Timmermann C et al. / Imperial continuous-infusion DMT neuroimaging literature (2023 and related).
  • ClinicalTrials.gov registry (U.S. National Library of Medicine) — live listings; status as of query date.
  • GH Research and other sponsor public disclosures (Phase 2 context; treat press materials as non-peer-reviewed unless published).
  • DEA/FDA research controls for Schedule I investigational use (regulatory framing).

Last editorial check: 2026-07-21. Research education only. Not a referral service. Not medical advice.